Adams Respiratory Therapeutics Added To NASDAQ Biotech Index

CHESTER, N.J., May 15 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. today announced that it was selected for addition to the NASDAQ Biotechnology Index(R) , effective with the open of trading on Monday, May 22, 2006.

"We are honored to be selected for inclusion in the NASDAQ Biotechnology Index," said Michael J. Valentino, president & CEO. "To join other leading companies in the NASDAQ Biotechnology Index is further recognition of Adams' successful business model and our dedication to building stockholder value. Since our IPO last July, our overall business has experienced tremendous growth, producing excellent results in both net sales and profits."

Launched in 1993, the NASDAQ Biotechnology Index includes securities of NASDAQ listed companies classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB), and which also meet other criteria. The NASDAQ Biotechnology Index is ranked on a semi-annual basis in May and November. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ National Market and meet specific criteria, including market value, average daily share volume and seasoning as a public company. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

Adams Respiratory Therapeutics, Inc.

CONTACT: Janet M. Barth, Adams Respiratory Therapeutics, Inc.,+1-908-879-2428

Back to news